EHR

Applied Science Releases New Advanced Technologies to Improve Care for People Living With Diabetes in Rural and Under-Served Communities

Co-created With Sierra Family Health Center and Western Sierra Medical Clinic, the Applied Science AdaptivMD Solution Integrates the Verily Retinal...

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025GAITHERSBURG, Md., Sept. 25, 2024...

Healthcare Software As A Service Market Surges to USD 68.5 Billion by 2030, Propelled by 10.7% CAGR – Verified Market Reports®

The Healthcare Software as a Service (SaaS) market is primarily driven by the increasing demand for cost-effective and scalable solutions...

Laboratory Information System Market Surges to USD 3.6 Billion by 2030, Propelled by 6.5% CAGR – Verified Market Reports®

The Laboratory Information System (LIS) market is primarily driven by the increasing demand for automation in laboratory processes, which enhances...

Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant

BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs

MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage...

error: Content is protected !!